Compare LYV & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYV | NTRA |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.1B | 39.1B |
| IPO Year | 2005 | 2015 |
| Metric | LYV | NTRA |
|---|---|---|
| Price | $181.69 | $270.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 15 |
| Target Price | $182.38 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 1.9M | 1.0M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,201,406,000.00 | $210,939,000.00 |
| Revenue This Year | $10.24 | $18.08 |
| Revenue Next Year | $9.37 | $19.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.83 | N/A |
| 52 Week Low | $125.34 | $134.85 |
| 52 Week High | $188.00 | $288.04 |
| Indicator | LYV | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 57.19 |
| Support Level | $158.87 | $261.63 |
| Resistance Level | $188.00 | $288.04 |
| Average True Range (ATR) | 4.96 | 10.88 |
| MACD | -0.51 | -1.77 |
| Stochastic Oscillator | 58.43 | 63.78 |
Live Nation is the largest live entertainment company in the world, serving as a concert promoter, venue operator, and ticketing platform. In addition, the firm generates revenue from sponsorships and advertising. With offices in 51 countries, Live Nation promotes concerts globally and it owned, operated, or had exclusive booking rights to more than 400 venues worldwide at the end of 2025, which the firm says makes it the second-largest operator of music venues globally. In 2025, Live Nation promoted nearly 55,000 events, drawing roughly 160 million fans. Ticketmaster is a dominant global ticketing service, selling nearly 650 million tickets in 2025.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.